3 'Strong Buy' Biotech Stocks to Buy Now, According to Top Analysts

Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy ratings from Top Wall Street analysts. Each stock offers solid upside potential, supported by fresh Buy calls.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential For more stock ideas, check out TipRanks' Analyst Top Stocks tool, which tracks the latest Buy ratings from top analysts in real time. Here are today's top analyst-backed stock picks. Click on any ticker to research the company before deciding whether to add it to your portfolio. Kyverna Therapeutics (KYTX) – Kyverna Therapeutics is a biotech developing CAR T-cell therapies for autoimmune diseases. Today, Leerink Partners analyst Thomas Smith maintained a Buy rating on the stock and increased the price target to $32 from $25 per share. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 195.75%. Pharvaris (PHVS) – Pharvaris is a clinical-stage biotech developing oral therapies for rare and life-threatening angioedema conditions. Today, Morgan Stanley analyst Maxwell Skor maintained a Buy rating on the stock with a price target of $41 per share. Interestingly, seven out of the eight Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 77.32%. Immunome (IMNM) – This is a biotech company developing targeted cancer and immune therapies. Today, Leerink Partners analyst Andrew Berens maintained a Buy rating on the stock with a price target of $40 per share. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 31.05%. Who Are the Top Analysts? TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks' Top Wall Street Analysts page.